European Union Authorizes AstraZeneca COVID-19 Vaccine for Use in Adults

The European Union regulators have greenlit the AstraZeneca COVID-19 vaccine for use in adults, addressing concerns over the pace of vaccination in the EU. This move comes after criticism of the European Medicines Agency for not acting quickly enough to vaccinate its population. However, concerns had been raised about the vaccine's efficacy in older individuals, with some questioning whether there was sufficient evidence to prove its effectiveness in this age group. The AstraZeneca vaccine, developed in collaboration with Oxford University, joins Pfizer and Moderna vaccines in being approved for use in the EU.

Key Takeaways:

• The European Union regulators have authorized the AstraZeneca COVID-19 vaccine for use in adults, covering people aged 18 and above.
• The European Medicines Agency (EMA) recommended two doses of the AstraZeneca vaccine, with the second shot administered 4 to 12 weeks after the first.
• The EMA stated that the recommended dosing regimen was shown to be safe and effective in preventing symptomatic COVID-19, with no severe cases and no hospitalizations more than 14 days after the second dose.
• AstraZeneca CEO Pascal Soriot welcomed the development, citing the vaccine's effectiveness, safety, and ease of administration.
• The EU had already ordered 300 million doses of the AstraZeneca vaccine and had options for an additional 100 million doses.

Statistics:

• 300 million doses of the AstraZeneca vaccine have been ordered by the EU.
• 100 million more doses of the AstraZeneca vaccine are available under options.
• The EMA recommended two doses of the AstraZeneca vaccine, with the second shot administered 4 to 12 weeks after the first.
• 14 days or less after the second dose, there were no severe cases or hospitalizations reported.

Sources:

• CBS News article, dated Friday, Jan. 29, 2021.
• European Medicines Agency press release, dated January 2021 (no specific date mentioned in the original text).